News
NBIX
136.88
-0.69%
-0.95
Noteworthy ETF Outflows: MDYG, OC, NBIX, BLD
NASDAQ · 2d ago
Weekly Report: what happened at NBIX last week (0318-0322)?
Weekly Report · 3d ago
Neurocrine Is Maintained at Overweight by JP Morgan
Dow Jones · 03/20 12:14
JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $158
Benzinga · 03/20 12:04
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR) with a Buy rating and a price target of $30. The analyst says Voyager’s TRACER capsid discovery platform has best-in-class potential for developing CNS-targeted in vivo gene therapies. The company is developing novel capsids to overcome limitations of central nervous system delivery.
Benzinga · 03/19 18:16
Neurocrine Biosciences To Participate At Stifel 2024 Virtual CNS Days Conference At 2:00 PM ET
NASDAQ · 03/19 17:01
Neurocrine Biosciences To Participate At UBS Virtual CNS Day Conference At 12:00 PM ET
NASDAQ · 03/18 15:01
Weekly Report: what happened at NBIX last week (0311-0315)?
Weekly Report · 03/18 09:05
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Arcellx Inc (ACLX) and Exact Sciences (EXAS)
TipRanks · 03/15 05:42
Hold Rating on Neurocrine Amidst Competitive Uncertainties and Clinical Trial Developments
TipRanks · 03/15 05:35
Neurocrine’s Market Edge Strengthened in CAH Treatment Following Competitor’s Drug Setback
TipRanks · 03/15 05:25
Spruce Biosciences Touches 52-Week Low After Unfavorable Genetic Disease Study Results
Spruce Biosciences touched a 52-week low Thursday following unfavorable clinical trial results and job cuts. The stock was recently down 81% to 97 cents. Spruce's results could help Neurocrine's crinecerfont, analysts say. The company's shares were recently down 2.5%.
Dow Jones · 03/14 18:31
Maintaining Hold Rating for Neurocrine Biosciences Amid Reduced Competition and Long-Term Market Potential
TipRanks · 03/14 11:15
Strong Buy on Neurocrine Biosciences as Crinecerfont Leads in CAH Market, Backed by Solid Pipeline and Underappreciated Value
TipRanks · 03/14 11:15
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)
TipRanks · 03/14 10:20
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences
Neurocrine Biosciences (NASDAQ:NBIX) is a research-based pharmaceutical company advancing drug candidates in the central nervous system. The average price target is $151.88 and 8 analysts have provided 12-month price targets of $200.00 for the company. The company has a positive revenue growth rate of 25.05% over the last three months.
Benzinga · 03/13 20:00
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
Neurocrine Biosciences has an average 12-month price target of $151.88. The company is a research-based pharmaceutical company advancing drug candidates in the central nervous system. 8 analysts have shared their insights on the company in the past three months.
Benzinga · 03/13 14:03
Neurocrine Price Target Raised to $200.00/Share From $170.00 by Oppenheimer
Dow Jones · 03/13 12:48
Neurocrine Is Maintained at Outperform by Oppenheimer
Dow Jones · 03/13 12:48
Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $200
Benzinga · 03/13 12:38
More
Webull provides a variety of real-time NBIX stock news. You can receive the latest news about Neurocrine Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.